← Leaderboards
Suzanne Craft
Wake Forest University Health Sciences
$45,089,134
Attributed
$51,763,507
Total exposure
19
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$79,191,195 · 21
By mechanism
P30$30,435,347 · 4
R01$16,445,942 · 8
RF1$15,841,653 · 2
R24$5,592,774 · 1
R37$5,193,310 · 1
T32$3,219,951 · 1
Top collaborators
- Carol A. Shively6 shared
- Christopher T Whitlow5 shared
- Gagan Deep2 shared
- Esther Seunghee Oh2 shared
- James R. Bateman1 shared
- Akiva Mintz1 shared
- Kiran Solingapuram Sai1 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Timothy M. Hughes$16,768,866
- Christopher T Whitlow$19,734,554
- Kiran Solingapuram Sai$5,408,657
- Joseph Aloysius McQuail$1,230,735
- Jeongchul Kim$670,806
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseParticipantBiological MarkersAdultCognitionMetabolicAmyloidDementiaCognitivePlasmaBrainInsulinMemoryBlood VesselsInsulin ResistanceMild Cognitive ImpairmentGlucoseResearch PersonnelCerebrospinal FluidBaseS Disease RiskInnovationCollaborations
Grant awards (108)
Alzheimer's Disease Research Center$3,043,318
P30 · FY2025 · AG · contact PI
Liquid biopsies to evaluate the effect of a ketogenic diet on molecular circuitries associated with mild cognitive impairment$752,765
R01 · FY2025 · AG
Administrative Core$386,843
P30 · FY2025 · AG · contact PI
Alzheimer's Disease Research Center$3,043,828
P30 · FY2024 · AG · contact PI
Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and Symptomatology$1,290,401
R24 · FY2024 · AG
Liquid biopsies to evaluate the effect of a ketogenic diet on molecular circuitries associated with mild cognitive impairment$763,947
R01 · FY2024 · AG
Administrative Core$386,843
P30 · FY2024 · AG · contact PI
Alzheimer's Disease Research Center$3,050,978
P30 · FY2023 · AG · contact PI
Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and Symptomatology$1,298,204
R24 · FY2023 · AG
PET imaging of microtubules in cognitively normal and impaired older adults$926,389
R56 · FY2023 · AG
Development of an Innovative Vervet (Chlorocebus aethiops sabaeous) Model of Early Alzheimerâs-like Neuropathology and Symptomatology$387,436
R24 · FY2023 · AG
Administrative Core$386,843
P30 · FY2023 · AG · contact PI
Alzheimer's Disease Research Center$3,053,179
P30 · FY2022 · AG · contact PI
Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and Symptomatology$1,305,223
R24 · FY2022 · AG
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment$1,014,666
R01 · FY2022 · AG · contact PI
Administrative Core$386,843
P30 · FY2022 · AG · contact PI
Alzheimer's Disease Research Center$3,046,092
P30 · FY2021 · AG · contact PI
Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and Symptomatology$1,311,510
R24 · FY2021 · AG
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment$1,068,699
R01 · FY2021 · AG · contact PI
Administrative Core$386,843
P30 · FY2021 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$2,878,019
P30 · FY2020 · AG · contact PI
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment$1,068,699
R01 · FY2020 · AG · contact PI
Conserved Transcriptional Response to Adversity (CTRA) and COVID-19: Role of Pre-existing Neighborhood Characteristics and Cognitive Impairment$316,108
P30 · FY2020 · AG · contact PI
Wake Forest ADCC Administrative Supplement$152,153
P30 · FY2020 · AG · contact PI
Core A: Administrative Core$137,963
P30 · FY2020 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$1,945,326
P30 · FY2019 · AG · contact PI
Multi-modal Imaging in a Diverse Cohort: The Wake Forest ADCC Neuroimaging Core$1,023,651
P30 · FY2019 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$309,715
P30 · FY2019 · AG · contact PI
Core A: Administrative Core$144,922
P30 · FY2019 · AG · contact PI
Effects of Western and Mediterranean Diets on Metabolic and Neuropathologic Risk Factors for Alzheimer's Disease in Nonhuman Primates$2,771,584
RF1 · FY2018 · AG
Wake Forest Alzheimer's Disease Core Center$1,770,906
P30 · FY2018 · AG · contact PI
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment$1,076,878
R01 · FY2018 · AG · contact PI
Core A: Administrative Core$530,145
P30 · FY2018 · AG · contact PI
Diversity Supplement to the Wake Forest Alzheimer's Disease Research Center$145,853
P30 · FY2018 · AG · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$3,435,574
RF1 · FY2017 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$1,746,797
P30 · FY2017 · AG · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$1,145,191
RF1 · FY2017 · AG · contact PI
Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment$954,203
R01 · FY2017 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$155,000
P30 · FY2017 · AG · contact PI
Core A: Administrative Core$130,207
P30 · FY2017 · AG · contact PI
Wake Forest Alzheimer's Disease Core Center$1,746,765
P30 · FY2016 · AG · contact PI
Beta-cell Function and Cognition in the Restoring Insulin Secretion (RISE) Study$519,974
R01 · FY2016 · DK · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$155,000
RF1 · FY2016 · AG · contact PI
Core A: Administrative Core$130,207
P30 · FY2016 · AG · contact PI
Beta-cell Function and Cognition in the Restoring Insulin Secretion (RISE) Study$453,383
R01 · FY2015 · DK · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$588,237
R37 · FY2014 · AG · contact PI
Beta-cell Function and Cognition in the Restoring Insulin Secretion (RISE) Study$453,722
R01 · FY2014 · DK · contact PI
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIR$190,026
P50 · FY2014 · AG · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$153,000
RF1 · FY2014 · AG · contact PI
Beta-cell Function and Cognition in the Restoring Insulin Secretion (RISE) Study$581,262
R01 · FY2013 · DK · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$574,628
R37 · FY2013 · AG · contact PI
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIR$177,732
P50 · FY2013 · AG · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$148,000
RF1 · FY2013 · AG · contact PI
Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD Biomarker$8,033,304
RF1 · FY2012 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$500,585
R37 · FY2012 · AG · contact PI
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIR$190,024
P50 · FY2012 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$513,467
R37 · FY2011 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$433,274
T32 · FY2011 · AG · contact PI
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIR$194,702
P50 · FY2011 · AG · contact PI
Oral Glucose Tolerance Test for Alzheimer's Disease Biomarker Development$191,060
R21 · FY2011 · AG
Glucose Regulation and Memory in Alzheimer's Disease$5,000
R37 · FY2011 · AG · contact PI
MCI, Insulin and Cholesterol in a Community Sample$585,463
R01 · FY2010 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$556,491
R37 · FY2010 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$423,399
T32 · FY2010 · AG · contact PI
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIR$191,944
P50 · FY2010 · AG · contact PI
Oral Glucose Tolerance Test for Alzheimer's Disease Biomarker Development$177,172
R21 · FY2010 · AG
MCI, Insulin and Cholesterol in a Community Sample$553,212
R01 · FY2009 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$435,110
R37 · FY2009 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$418,383
T32 · FY2009 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$125,661
R37 · FY2009 · AG · contact PI
The Effects of Rosiglitazone in Patients with MCI$99,694
R01 · FY2009 · AG · contact PI
MCI, Insulin and Cholesterol in a Community Sample$511,015
R01 · FY2008 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$480,409
R37 · FY2008 · AG · contact PI
Therapeutic Effects of Intranasal Insulin in AD$374,682
R01 · FY2008 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$291,470
T32 · FY2008 · AG · contact PI
Therapeutic Effects of Intranasal Insulin in AD$25,000
R01 · FY2008 · AG · contact PI
The Effects of Rosiglitazone in Patients with MCI$725,497
R01 · FY2007 · AG · contact PI
MCI, Insulin and Cholesterol in a Community Sample$496,594
R01 · FY2007 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$489,627
R37 · FY2007 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$415,028
T32 · FY2007 · AG · contact PI
Therapeutic Effects of Intranasal Insulin in AD$372,180
R01 · FY2007 · AG · contact PI
MCI, Insulin and Cholesterol in a Community Sample$33,260
R01 · FY2007 · AG · contact PI
MCI, Insulin and Cholesterol in a Community Sample$514,163
R01 · FY2006 · AG · contact PI
Glucose Regulation and Memory in Alzheimer's Disease$453,569
R37 · FY2006 · AG · contact PI
The Effects of Rosiglitazone in Patients with MCI$443,649
R01 · FY2006 · AG · contact PI
Neurobehavior, Neuroendocrinology, and Genetics of AD$414,786
T32 · FY2006 · AG · contact PI
Therapeutic Effects of Intranasal Insulin in AD$379,381
R01 · FY2006 · AG · contact PI
The Effects of Rosiglitazone in Patients with MCI$307,178
R01 · FY2006 · AG · contact PI
The Effects of Rosiglitazone in Patients with MCI$471,051
R01 · FY2005 · AG
Glucose Regulation and Memory in Alzheimer's Disease$470,526
R37 · FY2005 · AG
Neurobehavior, Neuroendocrinology, and Genetics of AD$418,898
T32 · FY2005 · AG
Neurobehavior, Neuroendocrinology, and Genetics of AD$404,713
T32 · FY2004 · AG
Insulin Resistance and CNS Function in Type 2 Diabetes$236,723
R01 · FY2004 · DK
GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE$199,195
R01 · FY2004 · AG
Insulin Resistance and CNS Function in Type 2 Diabetes$50,299
R01 · FY2004 · DK
Insulin Resistance and CNS Function in Type 2 Diabetes$236,723
R01 · FY2003 · DK
GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE$194,354
R01 · FY2003 · AG
Insulin Resistance and CNS Function in Type 2 Diabetes$274,995
R01 · FY2002 · DK
GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE$233,152
R01 · FY2002 · AG
Insulin and cortisol interactions in AD$0
P50 · FY2002 · AG
Insulin and cortisol interactions in AD$0
P50 · FY2002 · AG
GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE$210,417
R01 · FY2001 · AG
Insulin and cortisol interactions in AD$4,545
P50 · FY2001 · AG
Insulin and cortisol interactions in AD$0
P50 · FY2001 · AG
GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASE$209,867
R01 · FY2000 · AG
Insulin and cortisol interactions in AD$209,534
P50 · FY2000 · AG
Insulin and cortisol interactions in AD$4,545
P50 · FY2000 · AG
Insulin and cortisol interactions in AD$4,545
P50 · FY2000 · AG